Abiomed stock movement
Abiomed (ABMD), which is focused on native heart recovery with its Impella line of devices, has reported a 103.6% YTD (year-to-date) rise in the stock, from $192.49 on January 2, 2018, to $377.49 on September 7, 2018.
In the first quarter of fiscal 2019, which ended June 30, 2018, Abiomed reported revenues of $180 million, a YoY (year-over-year) rise of 35.9%. It reported sales of $152 million in the US market, driven by a 30% YoY rise in total patient utilization across both cardiogenic shock and protected PCI (percutaneous coronary intervention) indications. It reported sales of $22 million outside the United States in fiscal Q1 2019, which is a YoY rise of 75%. That was driven mainly by a 42% YoY rise in sales in the German market, coupled with the controlled launch of Impella in the Japanese market. The company managed to beat the Wall Street consensus revenue and EPS estimates by $6.74 million and $1.13, respectively, in fiscal Q1 2019.
To know more about Abiomed’s valuation, analysts’ recommendations, and revenue estimates, please refer to How Do Abiomed’s Valuations Look in September?
Increasing awareness for Impella
To increase the adoption of Impella devices, Abiomed is focused on training its internal staff and hiring new talent. In fiscal Q1 2019, it added 52 employees around the world. Fourteen of those are involved in commercialization of Impella in the US market. The company also trained more than 750 physicians to use Impella in fiscal Q1 2019.
Abiomed has trained 28 protected PCI coordinators who are involved in identifying patients eligible for treatment with Impella and collaborating with heart teams at hospitals. Currently, 60 hospitals have been supplied with a dedicated protected PCI coordinator. These coordinators also help identify patients from the community who are suffering from advanced coronary artery disease and eligible for treatment with Impella.